$JNJ Johnson &amp; Johnson pharmaceutical worldwide operational sales grew 3.9% driven by STELARA DARZALEX, IMBRUVICA, ERLEADA, TREMFYA, UPTRAVI, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA and OPSUMIT and offset by declines in REMICADE, VELCADE and ZYTIGA. 10K not yet available. https://t.co/7mkBkECVUS https://t.co/o8CN0gF1hD